INVESTORS & MEDIA

Regeneron Announces Presentation at the 29th Annual Canaccord Adams Global Growth ConferenceTARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 7, 2009-- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 29^th Annual Canaccord Adams Global Growth Conference on Wednesday, August 12, 2009. The presentation, which is scheduled for 2:30 p.m. Eastern Time, will provide an overview of the Company, including its three Phase 3 clinical programs. The session may be accessed through the Company’s web site, www.regeneron.com, on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through September 11, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

Source: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.
Peter Dworkin, 914-345-7640
Investor Relations
peter.dworkin@regeneron.com
or
Laura Lindsay, 914-345-7800
Media Relations
laura.lindsay@regeneron.com